Oculogenex is a biotech company focused on developing gene therapies to treat degenerative retinal diseases, specifically age-related macular degeneration (AMD). In March 2024, Oculogenex sent its pioneering gene therapy to the International Space Station (ISS) on SpaceX's 30th Commercial Resupply Services mission with NASA to test the therapy in the unique environment of space. Their work is funded in part by the ISS National Lab and Boeing. The company partners with organizations like Forge Biologics for manufacturing and process development.
All verified mentions of this organization in source documents.
Oculogenex will use the International Space Station to test a novel gene therapy intended to prevent and possibly reverse vision loss from age-related macular degeneration.